United States - English - NLM (National Library of Medicine)

professional complementary health formulas - betula alba 2x caltha palustris 3x galium aparine 3x sedum acre 3x thuja occidentalis 3x urtica urens 3x clematis erecta 4x hedera helix 4x juniperus communis 4x ononis spinosa 4x quillaja saponaria 4x sempervivum tectorum 4x echinacea angustifolia 5x calcarea fluorica 6x nitricum acidum 6x argentum metallicum 8x phosphorus 8x apis mellifica 12x pyrogenium 12x - for the temporary relief of minor aches, swelling, pain, or tingling of the joints, muscles, or extremities.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone dipropionate cream usp (augmented), 0.05% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. betamethasone dipropionate cream usp (augmented), 0.05% is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation. risk summary there are no available data on betamethasone dipropionate cream usp (augmented), 0.05% use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. advise pregnant women that betamethasone dipropionate cream usp (augmented), 0.05% may increase the risk of having a low birthweight infant and to use betamethasone dipropionate cream usp (augmented), 0.05% on the smallest area of skin and for the shortest duration possible. in animal reproduction studies, increased malformations, including umbilical hernias, cephalocele, and cleft palate, were observed after intramuscular administration of betamethasone dipropionate to pregnant rabbits. the available data do not allow the calculation of relevant comparisons between the systemic exposure of betamethasone dipropionate in animal studies to the systemic exposure that would be expected in humans after topical use of betamethasone dipropionate cream usp (augmented), 0.05% (see data). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data animal data betamethasone dipropionate has been shown to cause malformations in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. the abnormalities observed included umbilical hernias, cephalocele, and cleft palate. risk summary there are no data regarding the excretion of betamethasone dipropionate in breast milk, the effects on the breastfed infant, or the effects on milk production after topical application of betamethasone dipropionate cream usp (augmented), 0.05% to women who are breastfeeding. it is possible that topical administration of large amounts of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for betamethasone dipropionate cream usp (augmented), 0.05% and any potential adverse effects on the breastfed infant from betamethasone dipropionate cream usp (augmented), 0.05% or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breast milk, use betamethasone dipropionate cream usp (augmented), 0.05% on the smallest area of skin and for the shortest duration possible while breastfeeding. advise breastfeeding women not to apply betamethasone dipropionate cream usp (augmented), 0.05% directly to the nipple and areola to avoid direct infant exposure [see use in specific populations (8.4) ]. use of betamethasone dipropionate cream usp (augmented), 0.05% in pediatric patients younger than 13 years of age is not recommended due to the potential for hpa axis suppression [see warnings and precautions (5.1) ]. in an open-label hpa axis safety trial in subjects 3 months to 12 years of age with atopic dermatitis, betamethasone dipropionate cream (augmented), 0.05% was applied twice daily for 2 to 3 weeks over a mean body surface area of 58% (range 35% to 95%). in 19 of 60 (32%) evaluable subjects, adrenal suppression was indicated by either a ≤5 mcg/dl pre-stimulation cortisol, or a cosyntropin post-stimulation cortisol ≤18 mcg/dl and/or an increase of <7 mcg/dl from the baseline cortisol. out of the 19 subjects with hpa axis suppression, 4 subjects were tested 2 weeks after discontinuation of betamethasone dipropionate cream (augmented), 0.05%, and 3 of the 4 (75%) had complete recovery of hpa axis function. the proportion of subjects with adrenal suppression in this trial was progressively greater, the younger the age group. because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of systemic toxicity when treated with topical drugs. they are, therefore, also at greater risk of hpa axis suppression and adrenal insufficiency upon the use of topical corticosteroids. rare systemic effects such as cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients, especially those with prolonged exposure to large doses of high potency topical corticosteroids. local adverse reactions including skin atrophy have also been reported with use of topical corticosteroids in pediatric patients. avoid use of betamethasone dipropionate cream usp (augmented), 0.05% in the treatment of diaper dermatitis. clinical trials of betamethasone dipropionate cream (augmented), 0.05% included 104 subjects who were 65 years of age and over and 8 subjects who were 75 years of age and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. however, greater sensitivity of some older individuals cannot be ruled out.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride 5 mg in 1 ml - diltiazem hydrochloride injection is indicated for the following: temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. it should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in wolff-parkinson-white (wpw) syndrome or short pr syndrome. rapid conversion of paroxysmal supraventricular tachycardias (psvt) to sinus rhythm. this includes av nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the wpw syndrome or short pr syndrome. unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. the use of diltiazem hydrochloride injection should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impu

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - idarubicin hydrochloride (unii: 5vv3mdu5ie) (idarubicin - unii:zrp63d75jw) - idarubicin hydrochloride 1 mg in 1 ml - idarubicin hydrochloride injection, usp in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (aml) in adults. this includes french-american-british (fab) classifications m1 through m7.

United States - English - NLM (National Library of Medicine)

uriel pharmacy inc. - viscum album fruiting top (unii: bk9092j5mp) (viscum album fruiting top - unii:bk9092j5mp) - viscum album fruiting top 6 [hp_x] in 1 ml - directions: for oral use. use: temporary relief of headache.

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - dimethyl fumarate (unii: fo2303mni2) (monomethyl fumarate - unii:45iub1px8r) - dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. dimethyl fumarate delayed-release capsules are contraindicated in patients with known hypersensitivity to dimethyl fumarate or to any of the excipients of dimethyl fumarate delayed-release capsules. reactions have included anaphylaxis and angioedema [see warnings and precautions (5.1)]. risk summary there are no adequate data on the developmental risk associated with the use of dimethyl fumarate delayed-release capsules in pregnant women. in animals, adverse effects on offspring survival, growth, sexual maturation, and neurobehavioral function were observed when dimethyl fumarate (dmf) was administered during pregnancy and lactation at clinically relevant doses [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarr

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sherwood corporation (thailand) public company limited - permethrin (25:75::cis:trans); liquid hydrocarbon - emulsifiable concentrate - permethrin (25:75::cis:trans) pyrethroid active 500.0 g/l; liquid hydrocarbon solvent other 457.0 g/l - insecticide - adf clothing | aircraft | amenity area | fabric (cotton) - repellant treatment | felled log, post and pole | groundline treatmen - ant | auger beetle | beetle | biting fly | cockroach | drywood termite | flea | furniture beetle | lawn armyworm | mosquito | moth | pinhole borer | powderpost beetle | quarantine timber insects | silverfish | spider | subterranean termite | termite | timber beetle | adult | adult mosquitoes | argentine ant | cryptotermes brevis | cryptotermes domesticus | cryptotermes primus | ctenocephalides spp. | drywood termite | grass grub | ground fleas | large cockroach | lawn caterpillar | pharaoh ant | platypodiae | small cockroach | subterranean termite

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sherwood corporation (thailand) public company limited - bifenthrin; n-methyl-2-pyrrolidone; liquid hydrocarbon - emulsifiable concentrate - bifenthrin pyrethroid active 100.0 g/l; n-methyl-2-pyrrolidone solvent other 50.0 g/l; liquid hydrocarbon solvent other 649.0 g/l - insecticide - commercial area - general | commercial building/structure - external | domestic and/or public area | domestic building/structure - ant | cockroach | flea | fly | mosquito | paper nest wasp | spider | subterranean termite | tick - except paralysis tick | adult mosquitoes | argentine ant | ctenocephalides spp. | ground fleas | large cockroach | papernest wasps | pharaoh ant | small cockroach

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sherwood corporation (thailand) public company limited - imidacloprid - suspension concentrate - imidacloprid guanidine active 200.0 g/l - insecticide - building - post construction | building construction | reticulation system | soil treatment of poles | termite nest or colony | - giant termite | subterranean termite ex. m. darwiniensis | coptotermes spp. | giant northern termite | schedorhinotermes spp.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sherwood corporation (thailand) public company limited - imidacloprid - suspension concentrate - imidacloprid guanidine active 200.0 g/l - insecticide - apple | azalea - in pot | brassica spp. or cole crop | building protection from termite attack | capsicum or pepper | commercial - african black beetle - 1st instar larvae | aphid | azalea lace bug | bill bug - larvae | black peach aphid | bronze orange bug | brown flea beetle | cabbage aphid | chrysomelid beetle - larvae | citrus mealy bug | curl grub | elm leaf beetle | flatid | fuller's rose weevil | giant termite | green peach aphid | greenhouse thrip | harlequin bug | hibiscus flower beetle | longtailed mealy bug | melon thrips | mirids | pruinose scarab - first instar larvae | psyllid or lerp insect | scarab beetle - larva | silverleaf whitefly | soft scale | subterranean termite ex. m. darwiniensis | turnip aphid | woolly aphid | african black beetle larvae | argentinian scarab beetle larv | bemisia tabaci (biotype b) | billbug | coptotermes spp. | cotton whitefly | elm tree leaf beetle | giant northern termite | grey cabbage aphid | la plata weevil | lipaphis psuedobrassicae | pandanus planthopper | poinsettia whitefly | pruinose scarab larvae | schedorhinotermes spp.